Milrinone Stragen

Milrinone, the active ingredient in Milrinone Stragen, is a phosphodiesterase‑3 (PDE3) inhibitor presented as an intravenous solution for intravenous administration. It is used to improve cardiac output in patients with acute decompensated heart failure or cardiogenic shock, providing inotropic support and vasodilation in critical care settings.

GNH USA supplies Milrinone Stragen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, and specialty clinics worldwide, ensuring quality and regulatory compliance for critical care medicines through reliable logistics and validated cold‑chain handling where required.

Milrinone is a phosphodiesterase‑3 inhibitor used in the management of severe cardiac dysfunction. - Acute decompensated heart failure: improves cardiac output and reduces pulmonary congestion. - Cardiogenic shock: provides rapid inotropic support to maintain systemic perfusion. - Post‑cardiac surgery low‑output syndrome: enhances myocardial contractility and helps stabilize hemodynamics.

Milrinone may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Hypotension: reduction in blood pressure. - Arrhythmias: irregular heart rhythms. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Flushing: warmth and redness of skin. - Tachycardia: increased heart rate.

Serious or Rare Side Effects: - Severe hypotension: profound drop in blood pressure. - Ventricular arrhythmias: life‑threatening heart rhythm disturbances. - Myocardial ischemia: reduced blood flow to heart muscle. - Thrombocytopenia: low platelet count. - Allergic reactions: rash, itching, or anaphylaxis. - Elevated liver enzymes: potential hepatic involvement.

Milrinone requires careful monitoring and specific safety measures before and during therapy. - Monitor blood pressure: watch for hypotension. - Assess cardiac rhythm: observe for arrhythmias. - Adjust dose in renal impairment: reduce or monitor renal function. - Avoid use in severe aortic stenosis: risk of excessive hypotension. - Pregnancy: use only if benefits outweigh potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Milrinone can interact with other medications, altering its efficacy or safety profile.

Major Interactions (Avoid): - Concurrent use with other potent vasodilators: may cause severe hypotension. - Co‑administration with strong CYP3A4 inhibitors: increase plasma levels. - Use with other inotropes (e.g., dopamine) without monitoring: risk of arrhythmia.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt inotropic effect. - Diuretics: additive effect on blood pressure. - Anticoagulants: monitor for bleeding if hypotension occurs.